Present and future evolution of advanced breast cancer therapy

Álvarez, Ricardo H.

doi:10.1186/bcr2572

Cited by 54 publications

(40 citation statements)

References 130 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the samples examined here (71.7%) were categorized as NR, which was expected when considering that most targeted therapies used in breast cancer have a relatively low response rate and are suitable in only a small subset of patients. 43,50 The percentage of responsive samples identified by ChemoFx DRM in this study (7.6%) is consistent with the 11% breast cancer patient response rate for sunitinib seen clinically. 31,43 The similar response rates seen in the assay and the clinic suggest that this assay could be useful in determining whether sunitinb is appropriate for a particular breast cancer patient.…”

Section: Reference and Controlssupporting

confidence: 64%

“…43,50 The percentage of responsive samples identified by ChemoFx DRM in this study (7.6%) is consistent with the 11% breast cancer patient response rate for sunitinib seen clinically. 31,43 The similar response rates seen in the assay and the clinic suggest that this assay could be useful in determining whether sunitinb is appropriate for a particular breast cancer patient. The strength of the ChemoFx tool lays in the identification of the patient population that may benefit from sunitinib treatment before the treatment is initiated.…”

Section: Reference and Controlssupporting

confidence: 64%

See 1 more Smart Citation

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

Suchy¹,

Hancher²,

Wang³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Reference and Controlssupporting

confidence: 64%

Section: Reference and Controlssupporting

confidence: 64%

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

Suchy¹,

Hancher²,

Wang³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets WJCO 5 th Anniversary Special Issues (2): Breast cancer common cause of cancer death in women, worldwide [1] . Currently, breast cancer may be treated using multiple chemotherapeutic programs depending on the histologic and molecular classification, such as the presence of hormone (estrogen and progesterone) receptors and/or epidermal growth factor receptor 2 (referred to as ERBB2 or HER2).…”

Section: Topic Highlightmentioning

confidence: 99%

Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets

Koizume

Miyagi

2014

WJCO

View full text Add to dashboard Cite

Breast cancer is a leading cause of cancer death in women, worldwide. Fortunately, breast cancer is relatively chemosensitive, with recent advances leading to the development of effective therapeutic strategies, significantly increasing disease cure rate. However, disease recurrence and treatment of cases lacking therapeutic molecular targets, such as epidermal growth factor receptor 2 and hormone receptors, referred to as triple-negative breast cancers, still pose major hurdles in the treatment of breast cancer. Thus, novel therapeutic approaches to treat aggressive breast cancers are essential. Blood coagulation factor VII (fVII) is produced in the liver and secreted into the blood stream. Tissue factor (TF), the cellular receptor for fVII, is an integral membrane protein that plays key roles in the extrinsic coagulation cascade. TF is overexpressed in breast cancer tissues. The TF-fVII complex may be formed in the absence of injury, because fVII potentially exists in the tissue fluid within cancer tissues. The active form of this complex (TF-fVIIa) may stimulate the expression of numerous malignant phenotypes in breast cancer cells. Thus, the TF-fVII pathway is a potentially attractive target for breast cancer treatment. To date, a number of studies investigating the mechanisms by which TF-fVII signaling contributes to breast cancer progression, have been conducted. In this review, we summarize the mechanisms controlling TF and fVII synthesis and regulation in breast cancer cells. Our current understanding of the TF-fVII pathway as a mediator of breast cancer progression will be also described. Finally, we will discuss how this knowledge can be applied to the design of future therapeutic strategies. Key words: Breast cancer; Blood coagulation; Tissue factor; Coagulation factor VII; Gene regulation; Therapeutic strategy Core tip: Breast cancer is a worldwide problem. Difficulties with treating the disease and its recurrence persist due, in part, to a lack of therapeutic molecular targets. Blood coagulation factor VII (fVII) is generally produced in the liver. Tissue factor (TF), the cellular receptor for fVII, is an integral membrane protein that plays key roles in the extrinsic coagulation cascade. Formation of the TF-fVII complex causes contributes to the malignant phenotype of breast cancer cells. In this review, we summarize the breast cancer biology associated with the TF-fVII pathway. Further, we will discuss how these mechanisms can be targeted as therapeutics for this aggressive disease.Koizume S, Miyagi Y. Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

show abstract

“…MDA-MB-231 or JygMC(A) cell lines were plated at the density of 8x10 6 cells/well into 12-well plates (Corning). After 24 hr, the cells were treated with each specific test compound (0, 1, 10, and 100 µM of YC-1, G3, or CJ-3-60 respectively).…”

Section: Ce El Ll L--b Ba As Se Ed D W Wo Ou Un Nd D H He Ea Al Li mentioning

confidence: 99%

“…Some of these agents include angiogenesis inhibitors which targets angiogenesis, a critical step for the progression of breast cancer. The onset of angiogenesis is orchestrated by various physiological and pathological stimuli, chief among these is hypoxia [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Breast Cancer Angiogenesis and Metastasis ay Targeting Hypoxia-Inducible Factor-1α

Madu¹

View full text Add to dashboard Cite

DEDICATION"To (God) who is able to do immeasurably more than all we ask or imagine, according to his power that is at work within us"-Ephesians 3:20.And to my family-my wife, Pamela; and my children, Chinua and Elechi. For all you did to sustain my choice. Without you, this will not be.iv ACKNOWLEDGEMENTS I observe this dissertation today not as a completion of a search, but a celebration of success; symbolizing a temporary end as well as a beginning-signifying an achievement as well as triumph.This project culminating into this dissertation would not have been possible if it were not for the contributions and assistance I received from several people. In an attempt to express my appreciation, it will be very difficult to find words that have not already been used over again-a situation where statements will seem no longer sufficient and words inadequate. However I still wish to acknowledge the following persons who stood by me and contributed to make this long-nursed dream a reality.I would like thank my mentor, Dr Yi Lu, for the opportunity to work in his lab, and supervising this project. To my committee members, Dr Wei Li (for providing the compounds used in this project), Dr Leonard Lothstein (for his input, valuable discussions, and accessibility; for listening and reassuring), Dr Ram I Mahato (for his kind words of encouragement and permitting me to use his lab equipment), Dr Andrzej T Slominski (for his wise suggestions). Thank you for accepting to serve as members of this committee, your thoughtful criticism, and involvement during the course of this project. I would like to thank Dr liyuan Li for the lab training. I gratefully acknowledge Dr Pfeffer for his advice, and unending encouragement and support.My mother merits special thanks for her support and sacrifice through the years. So does my father-in-law, Obong Okon Mkpong, for his prayers and encouragement. Sufficient words fail me in expressing my gratitude to my wife, Eno-Obong Pamela, whose love, dedication, and relentless confidence in me was the driving force behind all of this. You are the bedrock upon which the past twelve years of my life have been built. My ambition was great, but your faith in me was greater. I love you dearly! To my children Chinua and Elechi, for their love, and understanding during the long years of my education, and sacrificially spending three summers with me in the lab-I promise, this is it! This project would never have been completed without the encouragement and devotion of all of you, and so many other family members and friends. In the words of President John F. Kennedy, "In your hands, more than mine, rest the final success of (my) course". Thank you! v ABSTRACTThe current clinical chemotherapy agents are not ideal for breast cancer as they are not curative, but only provide a modest extension of survival with sometimes a severely adverse effect on the patient's quality of life. There is, therefore, an urgent need to search for new and more effective anti-breast cancer drugs. However, the existing screening sy...

show abstract

Present and future evolution of advanced breast cancer therapy

Cited by 54 publications

References 130 publications

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets

Inhibition of Breast Cancer Angiogenesis and Metastasis ay Targeting Hypoxia-Inducible Factor-1α

Contact Info

Product

Resources

About